d1e30690_dic_NECT___Inclusion_completed__Cancer_type
[Title] A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer [Country] NO [Cancer type] 
Colorectal cancer
Nordic NECT - Inclusion completed
Cancer type